- Stocks
- Pharma & Healthcare
- Fortis Malar
Fortis Malar share price
NSE: FORTISMLRPharma & HealthcareMedical Care Facilities
Fortis Malar at a glance
With a market capitalisation of ₹97 Cr, it ranks 2696th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
Its return on equity was 12.0% in FY26. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹0 Cr (−100.0% year on year) and net profit ₹0 Cr (−96.4%), on a consolidated basis. Promoters held 62.71% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹97 CrRank 2696 on NSE
- Price to book
- 2.28×FY26
- EPS (TTM)
- ₹0.08to Q1 FY27
- ROE
- 12.0%FY26
- ROCE
- 13.8%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 8,096.7%FY26
- Book value / share
- ₹18.31FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Fortis Malar quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Revenue YoY | — | — | — | — | — | — | — | −100.0% |
| Net profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹4 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr |
| Net profit YoY | — | — | −99.3% | — | −88.9% | +100.0% | −113.9% | −96.4% |
| Net margin | — | — | — | 20,750.0% | 33.3% | — | — | — |
| EPS | ₹0.05 | ₹0.00 | ₹0.19 | ₹2.22 | ₹0.01 | ₹0.01 | −₹0.02 | ₹0.08 |
Fortis Malar financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹69 Cr | ₹86 Cr | ₹86 Cr | ₹59 Cr | ₹0 Cr | — |
| Operating profit | −₹18 Cr | −₹8 Cr | −₹7 Cr | −₹8 Cr | ₹1 Cr | — |
| Net profit | −₹8 Cr | −₹8 Cr | −₹15 Cr | ₹45 Cr | ₹0 Cr | — |
| EPS (₹) | −₹4.00 | −₹4.00 | −₹8.00 | ₹24.00 | ₹0.00 | — |
| Cash from operations | −₹1 Cr | ₹7 Cr | ₹6 Cr | −₹7 Cr | ₹2 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹89 Cr | ₹80 Cr | ₹64 Cr | ₹109 Cr | ₹30 Cr | ₹34 Cr |
Fortis Malar shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 62.71% | 62.71% | 62.71% | 62.71% | 62.71% | 62.71% |
| Domestic institutions | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% |
| Non-institutions | 37.22% | 37.22% | 37.22% | 37.22% | 37.22% | 37.22% |
Fortis Malar vs peers
The listed Pharma & Healthcare companies nearest to Fortis Malar by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MERCURYLABMercury Labs | — | — | — | ₹102 Cr | — | — |
| VAISHALIVaishali Pharma | ₹7.49 | +2.04% | −30.3% | ₹101 Cr | 124.8 | — |
| CONCORDConcord Drugs | — | — | — | ₹101 Cr | — | — |
| DENISCHEMDenis Chem Lab | — | — | — | ₹101 Cr | — | — |
| FORTISMLRFortis Malar | — | — | — | ₹97 Cr | — | — |
| RAAJMEDIRaaj Medisafe | — | — | — | ₹97 Cr | — | — |
| KHFMKHFM HOSPITALIT | ₹40.90 | +4.87% | −50.1% | ₹95 Cr | — | — |
Ask anything about Fortis Malar
Pivot answers on the live chart with evidence you can check, and tests strategies against FORTISMLR's own history. Try: “Why has FORTISMLR moved over the last three months?” · “Backtest a 50-day moving-average crossover on FORTISMLR over five years” · “Compare FORTISMLR with MERCURYLAB on margins and valuation”
Frequently asked questions about Fortis Malar
What is the market cap of Fortis Malar?
Fortis Malar's market capitalisation is ₹97 Cr (₹97 Cr) at the 22 Oct 2026 close, ranking 2696th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Fortis Malar?
Return on equity was 12.0% in FY26 and return on capital employed was 13.8% in FY26 (consolidated figures).
Is Fortis Malar a debt-free company?
Fortis Malar is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Fortis Malar's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Fortis Malar reported revenue of ₹0 Cr, −100.0% year on year, and net profit of ₹0 Cr, −96.4% year on year.
What is the shareholding pattern of Fortis Malar?
As of 30 Jun 2026: promoters 62.71%, domestic institutions 0.07%, non-institutions 37.22%.
Who are Fortis Malar's competitors?
The listed Pharma & Healthcare companies closest to Fortis Malar by market cap are Mercury Labs, Vaishali Pharma, Concord Drugs, Denis Chem Lab, Raaj Medisafe and KHFM HOSPITALIT.
Is Fortis Malar a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Fortis Malar's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FORTISMLR against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with F · all NSE stocks · this page as text